Itacitinib

Status
Phase 1
Condition
Lung Transplant
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

Itacitinib is a novel and selective JAK1 inhibitor.

Study Purpose

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >